GeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Rating of "Moderate Buy" from Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $72.33.

A number of brokerages have recently issued reports on WGS. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group boosted their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 18,006 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08. Following the completion of the sale, the chief executive officer now directly owns 53,140 shares of the company's stock, valued at approximately $4,154,485.20. This trade represents a 25.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Feeley sold 35,506 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the transaction, the chief financial officer now directly owns 2,472 shares of the company's stock, valued at approximately $231,923.04. This represents a 93.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,735 shares of company stock valued at $11,719,787. Company insiders own 27.30% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of WGS. Principal Financial Group Inc. bought a new position in shares of GeneDx in the 3rd quarter worth about $604,000. GSA Capital Partners LLP bought a new stake in GeneDx in the 3rd quarter valued at about $322,000. Royce & Associates LP bought a new stake in GeneDx in the 3rd quarter valued at about $1,201,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of GeneDx during the 3rd quarter worth about $2,547,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock worth $6,240,000 after buying an additional 110,666 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

GeneDx Stock Performance

NASDAQ WGS traded down $3.67 during trading on Friday, reaching $90.79. The company's stock had a trading volume of 371,492 shares, compared to its average volume of 614,321. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -46.32 and a beta of 1.91. GeneDx has a twelve month low of $7.72 and a twelve month high of $115.60. The business's fifty day moving average price is $84.69 and its 200-day moving average price is $70.37.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, analysts anticipate that GeneDx will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.